ResearcherShandong UniversityNo recent work listed
Yuanyuan Jiang
Matched on ORCID iD 0000-0002-7438-4081; OpenAlex author ID A5102787786. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers
Papers 7
- Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and G… Co-author DOI 10.1016/j.ejphar.2023.176157↗
- Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Co-author DOI 10.1038/s41420-023-01359-4↗
- COL17A1 facilitates tumor growth and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.09.049↗
- Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Co-author DOI 10.1017/erm.2021.26↗
- Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
- CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p. Co-author DOI 10.1007/s13277-015-3900-6↗
- Crystallographic analysis of NHERF1-PLCβ3 interaction provides structural basis for CXCR2 signaling in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2014.03.028↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yannan Xia · 2 shared papers, 2023 · strength 0.40
- Paper Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that … DOI 10.1016/j.ejphar.2023.176157↗
- Paper Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in precli… DOI 10.1038/s41420-023-01359-4↗
- Yumeng Wang · 2 shared papers, 2023 · strength 0.40
- Paper Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that … DOI 10.1016/j.ejphar.2023.176157↗
- Paper Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in precli… DOI 10.1038/s41420-023-01359-4↗
- Hanxiang Zhan · 2 shared papers, 2021–2022 · strength 0.26
- Shengtao Yuan · 1 shared paper, 2023 · strength 0.20
- Li Sun · 1 shared paper, 2023 · strength 0.19
- Shuangshuang Lu · 1 shared paper, 2021 · strength 0.16
- Dujuan Cao · 1 shared paper, 2021 · strength 0.16
- Jian Yang · 1 shared paper, 2022 · strength 0.15
- Yongzheng Li · 1 shared paper, 2022 · strength 0.15
- Zhaowei Sun · 1 shared paper, 2022 · strength 0.15
- Zhiyao Fan · 1 shared paper, 2022 · strength 0.15
- Yuqing Zhang · 1 shared paper, 2021 · strength 0.11
- Min Li · 1 shared paper, 2021 · strength 0.11
- Xiuhui Shi · 1 shared paper, 2021 · strength 0.11
- Zhijun Zhou · 1 shared paper, 2021 · strength 0.11
- Jingxuan Yang · 1 shared paper, 2021 · strength 0.11
- Mingyang Liu · 1 shared paper, 2021 · strength 0.11
- Courtney W. Houchen · 1 shared paper, 2021 · strength 0.11
- Jinping Zhang · 1 shared paper, 2016 · strength 0.08
- Zhe Yang · 1 shared paper, 2014 · strength 0.04
- Xiaoqing Guan · 1 shared paper, 2014 · strength 0.04
- Shuo Wang · 1 shared paper, 2014 · strength 0.04
- Chunying Li · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.